BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9275493)

  • 1. [Quality control of biological therapy in patients with tumors].
    Zhang S
    Zhonghua Yi Xue Za Zhi; 1996 Jul; 76(7):483-4. PubMed ID: 9275493
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical use of interleukin-2 in treating cancer.
    Patterson DL; Wiemann MC
    Indiana Med; 1991 Aug; 84(8):534-7. PubMed ID: 1918915
    [No Abstract]   [Full Text] [Related]  

  • 3. Adoptive cellular therapy.
    Urba WJ; Longo DL
    Cancer Chemother Biol Response Modif; 1990; 11():265-80. PubMed ID: 2223395
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
    Oldham RK
    Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
    [No Abstract]   [Full Text] [Related]  

  • 5. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
    West WH
    Immunol Ser; 1989; 48():79-92. PubMed ID: 2488327
    [No Abstract]   [Full Text] [Related]  

  • 6. Lymphokine-activated killer lymphocytes: extramural clinical trials.
    Sniecinski IJ
    Immunol Ser; 1989; 48():59-77. PubMed ID: 2488326
    [No Abstract]   [Full Text] [Related]  

  • 7. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
    Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
    Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
    Clark J; Longo DL
    Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
    [No Abstract]   [Full Text] [Related]  

  • 9. [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
    Nitta T
    No To Shinkei; 1992 Jul; 44(7):605-13. PubMed ID: 1419336
    [No Abstract]   [Full Text] [Related]  

  • 10. [Locoregional adoptive immunotherapy using LAK cells and IL-2 against liver metastases from digestive tract cancer].
    Ueda Y; Sonoyama T; Itoi H; Fujiwara H; Fuji N; Itoh T; Fujiki H; Yamashita T; Yoshimura T; Harada S; Okugawa K; Yamagishi H
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1962-5. PubMed ID: 11086454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adoptive immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes].
    van de Loosdrecht AA; Ossenkoppele GJ; Beelen RH
    Ned Tijdschr Geneeskd; 1989 Oct; 133(40):1994-5. PubMed ID: 2812087
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular immunotherapy of cancer.
    Topalian SL; Rosenberg SA
    Crit Care Med; 1990 Feb; 18(2 Suppl):S144. PubMed ID: 2298029
    [No Abstract]   [Full Text] [Related]  

  • 13. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
    Wolf JA; Grimm EA
    Curr Opin Oncol; 1989 Dec; 1(2):249-57. PubMed ID: 2489968
    [No Abstract]   [Full Text] [Related]  

  • 14. [Our experience with lymphocytes activated against cancer: CTL cells].
    Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
    G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes].
    Eggermont AM; Stoter G; Jansen RL; Bolhuis RL
    Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1387-92. PubMed ID: 2677757
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
    Lillehei KO; Johnson SD; McCleary EL; Mitchell DH; Schiltz PM; Kruse CA
    Online J Curr Clin Trials; 1993 Dec; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
    [No Abstract]   [Full Text] [Related]  

  • 17. Easing the side effects of IL-2-LAK cell therapy.
    Oncology (Williston Park); 1988 May; 2(5):61, 64. PubMed ID: 3275159
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukin-2: basic biology and therapeutic use.
    Williams TM; Fox KR; Kant JA
    Hematol Pathol; 1991; 5(2):45-55. PubMed ID: 1894582
    [No Abstract]   [Full Text] [Related]  

  • 19. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
    Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical/technical challenges in adoptive cellular immunotherapy: in vitro culture techniques.
    Yannelli JR; Jadus MR; Beckner S; Lacerna LV; Oldham RK
    Immunol Ser; 1989; 48():191-206. PubMed ID: 2488322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.